Navigation Links
Alfacell Reports Financial Results for First Quarter of Fiscal 2008

SOMERSET, N.J., Dec. 10 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported its financial results for the first quarter of fiscal 2008.

The company recorded a net loss of approximately $2.7 million, or $0.06 per basic and diluted common share, for the fiscal quarter ended Oct. 31, compared to a net loss of $2.4 million, or $0.05 per basic and diluted common share, for the first quarter of fiscal 2007. General and administrative expenses increased by approximately $0.2 million, and investment income decreased by approximately $0.1 million, during the first quarter of fiscal 2008 as compared to the same quarter a year ago.

Cash and Liquidity

As of Oct. 31, the company had cash and cash equivalents of approximately $5.4 million, a decrease of approximately $1.6 million from cash and cash equivalents of approximately $7.0 million at July 31. The company believes that this level of cash and cash equivalents is sufficient to support its activities through the first quarter of fiscal 2009 based on the current expected level of receipts and expenditures.

"Fiscal 2008 is off to a promising start," said Kuslima Shogen, Alfacell's chairman and chief executive officer. "Upon reaching the necessary number of evaluable events in our confirmatory Phase IIIb clinical trial for ONCONASE(R), we will begin the required statistical analysis. Our rolling NDA submission for ONCONASE continues as planned and is our primary focus in fiscal 2008."

Clinical Trials Update

Alfacell has completed patient enrollment in the confirmatory Phase IIIb clinical trial for ONCONASE (ranpirnase) in patients suffering from unresectable malignant mesothelioma. A total of 428 patients were enrolled in the trial. The company plans to begin the required statistical analysis of the data generated by the trial after 316 evaluable events have occurred. A total of 307 evaluable events have occurred to date.

The U.S. Food and Drug Administration (FDA) granted ONCONASE fast track status and orphan-drug designation for treatment of malignant mesothelioma. The rolling NDA submission for ONCONASE is in process, and Alfacell plans to submit the final clinical section within four months of reporting 316 evaluable events.

The company is focused on the imminent completion of the confirmatory Phase IIIb clinical trial and completion of the rolling NDA, and intends to initiate its planned Phase II oncology program for ONCONASE after the end of the Phase IIIb clinical trial.

Conference Call & Webcast

Alfacell will host a conference call and Webcast to discuss the financial results at 11 a.m. EST on Monday, Dec. 10. To participate in the live conference call, U.S. residents may dial 1-877-407-9205, and international callers may dial 1-201-689-8054 and reference Alfacell. A replay of the call will be available until Dec. 17. To access the replay, U.S. residents may dial 1-877-660-6853, and international callers may dial 1-201-612-7415 and enter account number 286 and conference ID number 264176. A live Webcast and replay of the conference call will be available on Alfacell's Web site at


ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in the outcome of the company's ongoing Phase IIIb clinical trial for its lead product, the company's ability to secure necessary approvals from regulatory agencies, uncertainties involving the ability of the company to finance research and development activities and its ongoing operations, potential challenges to or violations of patents, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Media Contact: Investor Contact:

David Schull or Wendy Lau Andreas Marathovouniotis

Russo Partners Russo Partners

212-845-4271 212-845-4253


Condensed Statements of Operations


Three-Months Ended

October 31

2007 2006

Revenues $- $-


Research and development 1,615,791 1,570,185

General and administrative 1,171,516 926,038

Total expenses 2,787,307 2,496,223

Loss from operations (2,787,307) (2,496,223)

Interest income, net 60,507 123,287

State tax benefit - -

Net loss $(2,726,800) $(2,372,936)

Net loss per common share-basic and diluted $(0.06) $(0.05)

Shares used in computation of net loss per

common share:

Basic and diluted 46,430,000 44,346,000

Balance Sheet Data:

October 31, July 31,

2007 2007

Cash and cash equivalents $5,397,768 $6,968,172

Total assets $6,425,242 $7,820,499

Current liabilities $1,922,984 $1,829,900

Accumulated deficit $(94,798,555) $(92,071,755)

Total stockholders equity $4,250,698 $5,778,480

SOURCE Alfacell Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
(Date:10/9/2015)... October 9, 2015 ... sich einer Kolonoskopie im Rahmen eines Screenings, ... Die NOCT-Studie bewertete auch die Compliance, Sicherheit, ... ® ) an erwachsenen Patienten vergleicht, ... Screenings, einer beobachtenden oder einer diagnostischen Kolonoskopie ...
(Date:10/9/2015)... -- --> --> ... of an Intellectual Property & Subsidiary Assignment and an Assignment & Assumption ... Corporation, related party, and a majority holder of 88% ... --> These agreements were executed as part of ... and Development components shall now be separate from the ...
(Date:10/9/2015)... India , October 9, 2015 ... --> The report ... market and overall status of the ... of guidance and direction for companies ... . ...
Breaking Medicine Technology:
... /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: ... patented biopharmaceutical, modernized traditional Chinese medicine, branded generics and ... Shareholder Meeting to the 26th floor, Conference Room E ... (EDT). Shareholders will be admitted beginning at 9:30 am. ...
... 2011 Bacterin International Holdings, Inc. (NYSE Amex: ... that it has scheduled a conference call ... to discuss the Company,s financial results for its fourth ...   Bacterin International Holdings, Inc. intends to issue its earnings ...
Cached Medicine Technology:
(Date:10/9/2015)... ... 09, 2015 , ... The American Osteopathic Foundation (AOF) has ... Education J. Michael Finley, DO, as the recipient of the 2015 W. Douglas ... on graduate medical education opportunities for osteopathic residents, and his dedication to promoting ...
(Date:10/9/2015)... ... October 09, 2015 , ... A new health tool that helps identify ... available online ( ) – just in time for the cold and flu ... October. However, for many in the U.S., the real start of cold/flu season is ...
(Date:10/9/2015)... ... October 09, 2015 , ... ... promotion on Invisalign, the orthodontic system that uses clear, plastic aligners. This alternative ... invisible against the teeth, which allow patients to complete treatment in privacy. Additionally, ...
(Date:10/9/2015)... Washington, DC (PRWEB) , ... October 09, 2015 , ... ... agreement from the US Centers for Disease Control and Prevention (CDC) to improve the ... 14 years that AAFA has been awarded a project by the CDC and allows ...
(Date:10/9/2015)... Ohio (PRWEB) , ... October 09, 2015 , ... ... United States, is welcoming individuals from all walks of life to save money ... the set price of $25 per month per medication, individuals and families can ...
Breaking Medicine News(10 mins):
... 12 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... on February 19, 2009, and will host a conference call to ... Eastern Time. , , , Date: ... Time, Conference call access:, Internet: ...
... Pamper Tired TootsiesBETHESDA, Md., Feb. 12 Valentine,s Day marks ... men and women. While the old adage "a way to ... true, another body part is gaining affection from both sexes ... (APMA) survey revealed 84 percent of women are embarrassed about ...
... MediCom Worldwide, Inc., an accredited provider of continuing medical ... of an online repository of resources and education on ... of health care practitioners.The goal of Managing ... to provide an extensive array of programs to support ...
... Scientists studying an inherited condition resulting in blindness and ... affect both eye function and normal tooth development. ... the formation of teeth and eyes has been uncovered ... in two families living in a village in the ...
... a key role in the prevention and treatment of ... Endothelial cells line the blood vessels and are critical ... , Researchers at the Centenary Institute have discovered ... cells. , Professor Jenny Gamble, Head of ...
... research will focus increasingly on electronic data, with less ... long term trend emerged at a recent conference on ... dealt with the challenges posed by the growing scale ... But in the more immediate future biological specimens will ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: